Mammaglobin: a candidate diagnostic marker for breast cancer

Zehentner, Barbara K.; Carter, Darrick

doi:10.1016/j.clinbiochem.2003.11.005

Cited by 74 publications

(73 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human mammaglobin (hMAM) is another breastspecific and breast cancer-associated marker in breast epithelial cells and it is over-expressed in breast cancer. hMAM known for its mammary tissue specificity and it has been discussed as a promising diagnostic marker in breast cancer [29]. In our study, the importance of these markers was also shown (p00.001 and p00.01) in the blood of breast cancer patients.…”

Section: Discussionsupporting

confidence: 69%

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Oloomi

Bouzari

Mohagheghi

et al. 2012

Cancer Microenvironment

View full text Add to dashboard Cite

A biomarker is a quantifiable laboratory measure of a disease specific biologically relevant molecule that can act as an indicator of a current or future disease state. The purpose of this study is to detect the expression of RNA biomarkers using Cytokeratin 19 (CK-19), Mammaglobin (MAM), Carcinoembryonic antigen (CEA), Mucin (MUC), C-Myc, erb-B2, a proliferation marker (Ki-67), Epidermal growth factor receptor (Her2/neu) and Estrogen receptor (ER) in Iranian women who were diagnosed with breast cancer. In this study, 90 samples; 60 cancer patients and 30 healthy controls were considered. 73.4 % patients were in stage I/II and 26.6 % were in stage III/IV. Patients were selected prior to the administration of any adjuvant systemic therapy. Total RNA extraction was obtained from peripheral blood of each patient and healthy control. Reverse transcription polymerase chain reaction (RT-PCR) method was used for detection of mRNA of the selected biomarkers of circulating breast cancer cells in blood. Molecular characterization is assessed as a method for early detection of breast cancer. For this purpose, eleven specific primers were selected and RT-PCR was used. The data of RT-PCR revealed that expression of MUC1, CK19, CEA, MAM, erbB-2, Ki67 and C-Myc biomarkers were significantly different between breast cancer patients and healthy controls. On the other hand, ERα, ERβ and Her2 markers were not significantly different between the two mentioned groups.

show abstract

Section: Discussionsupporting

confidence: 69%

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Oloomi

Bouzari

Mohagheghi

et al. 2012

Cancer Microenvironment

View full text Add to dashboard Cite

show abstract

“…The hMAM gene was described to be a potentially specific marker for the detection of circulating breast cancer cells [34]. However, the clinical relevance of the detection of hMAM positivetumour cells in the peripheral blood of patients with localised breast cancer still remains elusive, since several papers report conflicting results [35][36][37].…”

Section: Discussionmentioning

confidence: 99%

“…This may explain the occurrence of a single false-positive result in a healthy donor sample. In addition, other groups reported the detection of mammaglobin transcript in non-breast tissues, such as ovary, uterus, cervix and sebaceous glands [37,39,40].…”

Section: Discussionmentioning

confidence: 99%

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Marques

Teixeira

Diamond

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

International audienceHuman mammaglobin (hMAM) mRNA is a sensitive and specific marker of breast cancer cells. We evaluated if hMAM mRNA detection in serial peripheral blood samples from non-metastatic breast cancer patients predicts for disease recurrence. Patients scheduled for adjuvant or neoadjuvant chemotherapy were eligible. Serial blood samples were collected up to 5 years, the first before (neo)adjuvant chemotherapy. hMAM gene expression was analysed by RT-PCR. Specificity was evaluated in blood samples from healthy volunteers. A total of 321 patients were included. The incidence of pre-chemotherapy hMAM-positive samples was similar in patients who latter experienced cancer recurrence (22.4%) and those who remained disease-free (17.9%; = 0.46). Similarly, the mean number of positive follow-up samples was similar in both groups (0.15 ± 0.22 and 0.13 ± 013; = 0.29). Furthermore, there was no difference in disease-free (= 0.63) or overall survival (= 0.57) in patients with and without positive baseline samples or between patients whose follow-up samples were always hMAM negative and those with at least one positive sample. Multivariate survival analysis confirmed that hMAM mRNA detection before or after (neo)adjuvant chemotherapy was not predictive of recurrence. There is no evidence that hMAM mRNA detection at diagnosis or during follow-up predicts for breast cancer recurrence

show abstract

“…However, there are several factors such as pseudogenes, background gene expression and aberrant expression of epithelial genes in mesenchymal cells under several physiological or physiopathological conditions that can reduce the specificity of the assay and give rise to an unacceptable incidence of falsepositive results (Zippelius et al, 1997;Jung et al, 1998Jung et al, , 1999Ruud et al, 1999;Krüger et al, 2001;Jiang et al, 2002). Mammaglobin (MAM) and maspin are markers of major interest because some evidence indicates that they have a stronger relationship with breast tissue than several other epithelial markers such as cytokeratins, CEA and MUC-1 (Luppi et al, 1996;Zach et al, 1999;Grünewald et al, 2000;Ballestrero et al, 2001;Corradini et al, 2001;Silva et al, 2002;Zehentner and Carter, 2004).…”

mentioning

confidence: 99%

“…Although both MAM and maspin are frequently used for detection of occult tumour cells in peripheral blood, bone marrow and lymph nodes (Luppi et al, 1996;Zach et al, 1999;Grünewald et al, 2000;Ballestrero et al, 2001;Corradini et al, 2001;Silva et al, 2002;Zehentner and Carter, 2004), their specificity has been questioned by some authors (Min et al, 1998;Merrie et al, 1999;López-Guerrero et al, 1999;Suchy et al, 2000).…”

mentioning

confidence: 99%

Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer

et al. 2005

View full text Add to dashboard Cite

In cancer patients, the ability to detect disseminated tumour cells in peripheral blood or bone marrow could improve prognosis and consent both early detection of metastatic disease and monitoring of the efficacy of systemic therapy. These objectives remain elusive mainly due to the lack of specific genetic markers for solid tumours. The use of surrogate tissue-specific markers can reduce the specificity of the assays and give rise to a clinically unacceptable false-positive rate. Mammaglobin (MAM) and maspin are two putative breast tissue-specific markers frequently used for detection of occult tumour cells in the peripheral blood, bone marrow and lymph nodes of breast cancer patients. In this study, it was evaluated whether MAM and maspin gene expression may be induced in the normal blood and bone marrow cells exposed to a panel of cytokines, including chemotactic factors (C5a, interleukin (IL)-8), LPS, proinflammatory cytokines (TNF-a, IL-1b) and growth factors (IL-3, granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor). The experimental data show that all cytokines included in the panel, except for IL-8, were able to induce maspin expression; on the contrary, MAM gene was never induced. These results suggest that MAM is more specific than maspin and that the possible interference of cytokines should be taken into account in interpreting molecular assays for detection of isolated tumour cells.

show abstract

Mammaglobin: a candidate diagnostic marker for breast cancer

Cited by 74 publications

References 45 publications

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer

Contact Info

Product

Resources

About